Desktop wide screen and notebook header

  • Limited 10% discount on monthly subscriptions @ subscribe to The middle Road | The middle Road supports Melinda Gates backed Techstars Future of Longevity Accelerator

Tablets header

  • Limited 10% discount on monthly subscriptions @ subscribe to The middle Road | The middle Road supports Melinda Gates backed Techstars Future of Longevity Accelerator

Mobile header

  • Limited 10% discount on monthly subscriptions @ subscribe to The middle Road | The middle Road supports Melinda Gates backed Techstars Future of Longevity Accelerator

COVID-19 Vaccine update and Pfizer

Anthony Fauci ”  “More than 90 per cent, close to 95 per cent,” on the Pfizer vaccine

Pfizer AND BIONTECH announced a very positive update to their upcoming COVID-19 vaccine. Pfizer mRNA vaccine candidate, BNT162b2 is more than 90% effective in preventing COVID-19 among people with no prior evidence of SARS-CoV-2 infection. The study enrolled 43,538 participants and evaluated 94 confirmed cases of the novel coronavirus among the trial participants. The study did not encounter any serious adverse effects of administrating the vaccine among the participants. The first interim analysis in the global phase 3 study is a significant achievement based on the evidence provided during the study. The Monday morning news caused a 7.69% spike in the Pfizer stock price over the Friday evening closing price. Pfizer had a closing market capitalization of $214.665B and trading at a PE (TTM) of 25.11 at the closing price on 13 November.